GE HealthCare today announced a $138 million investment to expand its Carrigtohill, Cork contrast media fill and finish manufacturing site in Ireland. A new state-of-the-art facility on the grounds of ...

The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.

A new EMA approval has expanded the use of Vertex Pharma’s cystic fibrosis therapy ... including Denmark and Ireland. "Today’s approval brings us closer to our ultimate goal of providing ...

NMI®, a global leader in embedded payments infrastructure, announces NMI Customer Token Vault, a new extension to the NMI Gateway. Customer Token Vault introduces network tokenization with dynamic ...

Jazz Pharmaceuticals has agreed another pipeline ... head of R&D at Dublin, Ireland-headquartered Jazz. “Redx has discovered a number of preclinical KRAS candidates and we plan to leverage ...

Vertex Pharmaceuticals ( VRTX) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs, and ...

BofA analyst Tazeen Ahmad raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $540 from $522 and keeps a Buy rating on the ...

Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company known for its cystic fibrosis (CF) treatments, is at a critical juncture as it seeks to diversify its portfolio and maintain its ...

Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming the healthcare ...

JOSEPH PREZIOSO / AFP via Getty Images Vertex Pharmaceuticals' non-opioid painkiller received approval from the Food and Drug Administration. The drugmaker said the twice-daily pill, Journavx ...

Vertex Pharmaceuticals ( VRTX 5.31%) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 days. On Dec. 20, 2024, the FDA gave a thumbs-up to Alyftrek in treating cystic ...